Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
By M. Overman, S. Lonardi, K. Wong, H. Lenz, F. Gelsomino, M. Aglietta, M. Morse, E. Cutsem, R. McDermott, A. Hill and 11 more. Journal of Clinical Oncology, 2018
1,702 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/4ba18c627aa4f9f9e8957fa52a0f78794107d23b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 (2019, neutral): “KRAS/BRAF/NRAS wild type 11 (18) 6 (9)”
- Cytotoxic CD8+ T cells in cancer and cancer immunotherapy (2020, background): “The combination of PD-1/PD-L1 inhibitors with a CTLA-4 inhibitor has shown promise, as evidenced by the approval of nivolumab in combination with ipilimumab for the treatment of metastatic melanoma, advanced renal cell carcinoma and mismatch repair-deficient (dMMR) colorectal cancer.(44,45) In addit”
- Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids (2018, neutral): “We focused on dMMR CRC, given its high mutational load (Cancer Genome Atlas Network, 2012) and frequent response to anti-PD-1 therapy (Le et al., 2015, 2017; Overman et al., 2017, 2018).”
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, background): “In the same cohort of patients, a combination of nivolumab and ipilimumab showed better ORR than with nivolumab alone, which led to accelerated approval of the combination regimen for this group of patients on 11 July 2018, provided patients could tolerate this combination [44] (Category 2A).”
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer (2019, background): “For instance, 1 mg/ kg nivolumab plus 3 mg/kg ipilimumab every 3 weeks was effective dose for treatment of metastatic melanoma and esophagogastric cancer, whereas 3 mg/kg nivolumab plus 1 mg/kg ipilimumab every 3 weeks was effective dose for metastatic renal cell carcinoma, metastatic colorectal can”